Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in Europe and North America and approximately 1% in Asia and South America.

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.

An FDA advisory panel gave a unanimous verdict for an interatrial shunt in heart failure: no way.

Guideline-recommended therapies for heart failure (HF) were found to be ineffective in patients with HF caused by Chagas ...

Two NEJM trials report conflicting results on long-term beta-blockers after MI in patients with preserved ejection fraction, ...

Young adults are increasingly facing type 2 diabetes risk due to stress and unhealthy habits, even if they appear thin. Doctor highlights this alarming trend. A breakthrough drug, Mounjaro, is showing ...

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with ...

Clonal hematopoiesis of indeterminate potential (CHIP) subtypes, specifically non- DNMT3A genes, were associated with incident heart failure in older patients in a recent study published in JAMA ...

A first-in-human study suggested that tirzepatide — a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist — modulated abnormal activity in the brain’s nucleus accumbens, ...